Saudi Food And Drug Authority Approves Pemazyre For Advanced Cholangiocarcinoma Treatment Options

The Saudi Food and Drug Authority (SFDA) has approved Pemazyre (Pemigatinib) for adults with advanced cholangiocarcinoma. This approval is for those with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, who have not responded to previous treatments. Pemazyre functions by inhibiting FGFR2 on cancer cells, which plays a significant role in tumour growth.

The SFDA's decision followed a thorough evaluation of Pemazyre's efficacy, safety, and quality. Clinical studies revealed an objective response rate (ORR) of 37%, with complete responses in 2.8% of patients and partial responses in 34.3%. These findings suggest that Pemazyre offers a promising treatment option for patients with limited alternatives after other therapies have failed.

In clinical trials, the most common side effects were hyperphosphatemia, alopecia, diarrhoea, dry mouth, fatigue, and taste disturbances. Eye changes were also noted, necessitating regular monitoring during treatment to ensure patient safety. The SFDA emphasised that the registration was based on accelerated approval principles.

This approach relies on response rates and duration as indicators of long-term benefits. However, confirmatory studies are required to establish these benefits conclusively over time. The SFDA believes that Pemazyre can improve disease control and extend survival for patients with few treatment options.

The registration aligns with the SFDA's commitment to fostering innovation in healthcare and expanding treatment options for patients. This initiative supports the goals of Saudi Arabia's Vision 2030 Health Sector Transformation Program by enhancing quality of life and ensuring healthcare system sustainability.

Pemazyre's approval represents a significant step forward in providing new therapeutic avenues for individuals battling cholangiocarcinoma. By targeting FGFR2 receptors specifically involved in tumour progression, this drug offers hope for improved outcomes in a challenging medical landscape.

With inputs from SPA